시장보고서
상품코드
1485056

신경교종 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 질병별, 치료 유형별, 등급별, 최종 사용자별, 지역별, 경쟁사별(2019-2029년)

Glioma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease, By Treatment Type, By Grade, By End user, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경교종 치료 세계 시장 규모는 2023년 85억 4,000만 달러로 평가되었고, 2029년까지 7.25%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장을 보일 것으로 예상됩니다.

세계 시장 세분화는 암 치료제의 광범위한 전망에서 역동적이고 중요한 부문입니다. 신경교종은 뇌와 척수에서 발생하는 종양의 일종으로 복잡하고 어려운 치료 상황으로 알려져 있습니다. 신경교종 시장은 지속적인 연구, 기술 혁신 및 보다 효과적인 치료 접근 방식을 추구하는 것이 특징입니다. 신경교종 치료 세계 시장의 주요 촉진요인으로는 보다 안전하고 정확한 종양 절제술을 가능하게 하는 신경외과 기술 및 장비의 상당한 발전을 들 수 있습니다. 이러한 발전은 신경교종 환자의 예후를 개선하고 수술과 관련된 합병증 위험을 낮추고 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 85억 4,000만 달러
시장 규모 : 2029년 126억 5,000만 달러
CAGR : 2024-2029년 7.25%
급성장 부문 성상세포종
최대 시장 북미

표적 치료제의 개발은 신경교종 치료에 혁명을 가져올 또 다른 중요한 원동력입니다. 표적 치료제는 종양 성장을 가속하는 특정 분자 경로를 억제하는 것을 목표로 합니다. 여기에는 티로신 키나아제 억제제 및 단일 클론 항체와 같은 치료법이 포함되며, 일부 신경교종 환자에서 효과가 입증된 바 있습니다. 이러한 치료법은 보다 맞춤화되고 독성이 적은 치료의 가능성을 제공합니다. 면역치료는 종양학에서 빠르게 발전하고 있는 분야로, 신경교종 치료에도 적용되고 있습니다. 면역 체크포인트 억제제와 백신은 신경교종과 싸우기 위해 환자의 면역 체계를 활용하기 위해 연구되고 있습니다. 이러한 치료법은 아직 실험 단계에 있지만, 신경교종 치료의 패러다임을 바꿀 수 있는 잠재력을 가지고 있습니다.

조기 발견, 조기 진단에 대한 관심이 높아지면서 신경교종을 더 일찍, 더 치료 가능한 단계에서 식별할 수 있게 되었으며, MRI 및 PET 스캔과 같은 신경 영상 진단 기술의 발전으로 임상의는 더 높은 정확도로 신경교종을 감지하고 모니터링할 수 있게 되었습니다. 특히 고령화 지역에서의 신경교종 발생률 증가는 치료 시장 확대에 기여하고 있습니다. 노인 인구가 계속 증가함에 따라 신경교종 치료에 대한 수요는 계속 증가할 것으로 예상됩니다. 혁신적인 신경교종 치료법 개발은 주로 학계, 제약사, 연구기관의 협력에 의해 촉진되는 연구 개발의 확대가 중심이 되고 있습니다. 이러한 연구는 분자 표적 치료와 정밀의료 접근법에 초점을 맞춘 새로운 약물 후보물질과 치료법 탐색으로 이어지고 있습니다. 우호적인 규제 환경도 신경교종 치료 시장 형성에 중요한 역할을 하고 있습니다. 전 세계 규제 당국은 의약품 승인을 간소화하고 유망한 치료법이 환자에게 더 빨리 도달할 수 있도록 노력하고 있습니다. 개인 맞춤형 의료의 도입은 신경교종 치료의 주요 트렌드로 부상하고 있습니다. 유전자 프로파일링과 바이오마커 검사는 신경교종의 특정 아형을 식별하고 치료 결정에 도움을 줄 수 있습니다. 이러한 접근법을 통해 환자는 특정 종양 특성에 가장 효과적일 가능성이 높은 치료를 받을 수 있습니다.

의약품 개발의 필수 요소인 임상시험은 신경교종 치료의 혁신의 최전선에 있습니다. 이러한 임상시험은 표적치료, 면역치료, 병용요법 등 새로운 치료 접근법을 평가합니다. 이는 환자들에게 희망을 주고 이 분야의 발전을 촉진합니다. 환자 지원 단체와 지원 조직도 신경교종 치료 시장에서 중요한 역할을 하고 있습니다. 이들은 필수적인 자원을 제공하고, 연구비 증액을 옹호하며, 신경교종과 그 환자와 가족에게 미치는 영향에 대한 인식을 높이고 있습니다. 이 단체들은 치료 옵션을 형성하고 환자들이 치료에서 발언권을 가질 수 있도록 하는 데 큰 역할을 하고 있습니다. 이러한 발전과 미래에도 불구하고 신경교종 치료 시장에는 도전과제가 없는 것은 아닙니다. 신경교종의 복잡하고 이질적인 특성은 연구자와 임상의에게 계속해서 어려운 과제를 안겨주고 있습니다.

요약하자면, 세계 신경교종 시장은 지속적인 연구, 기술 혁신, 보다 효과적인 치료법을 끊임없이 추구하는 것이 특징입니다. 신경외과, 표적치료, 면역치료, 조기발견, 환자 수 증가, 연구 이니셔티브 확대, 지지적 규제, 맞춤형 의료, 임상시험, 강력한 환자 옹호 등이 모두 시장의 역동적인 성장에 기여하고 있습니다. 신경교종 치료 환경이 발전함에 따라 환자와 의료 서비스 제공업체는 치료 옵션과 치료 결과의 개선으로 인해 밝은 전망을 기대할 수 있습니다.

시장 성장 촉진요인

우호적인 규제 환경

신경교종 발생률 증가

주요 시장 과제

치료에 대한 내성

신경교종 불균일성

높은 치료비

혁신적 치료법에 대한 접근성 제한

주요 시장 동향

맞춤형 의료

병용요법

면역치료의 발전

신경 영상 강화

환자 중심의 케어 모델

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별(성상세포종, 올리고아스트로세포종, 희소돌기아교종)
    • 치료 유형별(수술, 화학요법, 방사선 요법, 기타)
    • 등급별(저등급, 고등급)
    • 최종사용자별(병원 및 진료소, 외래수술센터(ASC), 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 지역별

제5장 아시아태평양의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 신경교종치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 질환별
    • 치료 유형별
    • 등급별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 신경교종치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • F. Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals LLC
  • Merck & Co. KGaA
  • Sun Pharmaceutical Industries Ltd
  • Amgen Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Amneal Pharmaceuticals Inc
  • Karyopharm Therapeutics Inc
  • Biocon Ltd

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Glioma Treatment Market was valued at USD 8.54 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2029. The Global Glioma Treatment Market is a dynamic and vital segment within the broader landscape of oncology therapeutics. Gliomas, a group of tumors originating in the brain and spinal cord, are known for their complexity and challenging treatment landscape. The market for glioma treatment is characterized by continuous research, innovation, and the pursuit of more effective therapeutic approaches. Key drivers of the Global Glioma Treatment Market include significant advances in neurosurgery techniques and equipment, allowing for safer and more precise tumor resection. These advancements have enhanced the prognosis for glioma patients and reduced the risk of complications associated with surgery.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.54 Billion
Market Size 2029USD 12.65 Billion
CAGR 2024-20297.25%
Fastest Growing SegmentAstrocytoma
Largest MarketNorth America

The development of targeted therapies is another pivotal driver, revolutionizing the treatment of gliomas. Targeted agents aim to interfere with specific molecular pathways that fuel tumor growth. They include therapies like tyrosine kinase inhibitors and monoclonal antibodies, which have demonstrated efficacy in subsets of glioma patients. These therapies offer the potential for more tailored and less toxic treatment options. Immunotherapies, a rapidly evolving field in oncology, have also made inroads into glioma treatment. Immune checkpoint inhibitors and vaccines are being explored to harness the patient's immune system in the fight against glioma. Although these treatments are still in the experimental stage, they hold promise in changing the treatment paradigm for gliomas.

Early detection and diagnosis initiatives have gained prominence, allowing for the identification of gliomas at earlier, more treatable stages. Advances in neuroimaging techniques, such as MRI and PET scans, enable clinicians to detect and monitor gliomas with higher precision. The growing incidence of glioma, particularly in regions with an aging population, has contributed to the expansion of the treatment market. As the elderly population continues to grow, the demand for glioma treatments is expected to rise. Expanding research efforts, often facilitated by collaborative partnerships between academic institutions, pharmaceutical companies, and research organizations, are central to the development of innovative glioma therapies. This research has led to the exploration of novel drug candidates and treatment modalities, with a focus on molecularly targeted therapies and precision medicine approaches. A supportive regulatory environment has also played a crucial role in shaping the glioma treatment market. Regulatory agencies worldwide are working to streamline drug approvals and ensure that promising treatments reach patients more quickly. The adoption of personalized medicine is emerging as a key trend in glioma treatment. Genetic profiling and biomarker testing help identify specific subtypes of gliomas and guide treatment decisions. This approach ensures that patients receive therapies that are most likely to be effective for their particular tumor characteristics.

Clinical trials, an essential component of drug development, are at the forefront of innovations in glioma treatment. These trials assess new therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments. They offer hope for patients and drive progress in the field. Patient advocacy groups and support organizations have also played a significant role in the glioma treatment market. They provide essential resources, advocate for increased research funding, and promote awareness of gliomas and their impact on patients and families. These groups have been instrumental in shaping treatment options and ensuring that patients have a voice in their care. Despite the progress and promise, the glioma treatment market is not without challenges. High treatment costs, resistance to therapies, and access to novel treatments remain persistent issues.The complex and heterogeneous nature of gliomas continues to pose a formidable challenge for researchers and clinicians.

In summary, the Global Glioma Treatment Market is characterized by ongoing research, innovation, and a relentless pursuit of more effective therapies. Advancements in neurosurgery, targeted therapies, immunotherapies, early detection, a growing patient population, expanding research initiatives, supportive regulations, personalized medicine, clinical trials, and strong patient advocacy all contribute to the dynamic growth of the market. As the glioma treatment landscape evolves, patients and healthcare providers can anticipate a brighter outlook with improved treatment options and outcomes.

Key Market Drivers

Supportive regulatory environment

A supportive regulatory environment plays a crucial role in driving the Glioma Treatment Market. Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are working collaboratively with pharmaceutical companies and researchers to streamline drug approvals and ensure that promising glioma treatments reach patients more swiftly and efficiently. One of the key ways a supportive regulatory environment impacts the market is through accelerated drug development and approval processes. Gliomas are aggressive and often fatal, necessitating timely access to innovative treatments. Regulatory agencies are increasingly open to expediting the approval of drugs that demonstrate promising results in early clinical trials. This accelerates the availability of new therapies for glioma patients, potentially extending their survival and improving their quality of life.

The regulatory environment is conducive to fostering a collaborative approach in drug development. Regulatory agencies work with pharmaceutical companies to facilitate the design of clinical trials, allowing for more efficient data collection and analysis. This collaborative effort ensures that the studies meet the necessary criteria for evaluating treatment efficacy. The regulatory agencies provide guidance and support for researchers and pharmaceutical companies in designing innovative clinical trial protocols. This includes the development of novel endpoints and outcome measures, which can better reflect the therapeutic benefits of emerging glioma treatments. Such guidance is invaluable in shaping the clinical trial landscape and ensuring that studies are well-designed and capable of demonstrating a treatment's effectiveness.

A supportive regulatory environment is instrumental in encouraging investment in glioma research and development. Pharmaceutical companies are more inclined to allocate resources to glioma drug discovery when they see a collaborative and efficient regulatory process. This fosters a conducive atmosphere for innovation and advances in glioma treatment options.

In conclusion, a supportive regulatory environment is a driving force in the Glioma Treatment Market. By expediting drug development, fostering collaboration, providing guidance for clinical trials, and encouraging research investment, regulatory agencies are instrumental in ensuring that promising glioma treatments reach patients more rapidly. This not only benefits patients by offering access to innovative therapies but also stimulates further research and development in the field, ultimately shaping the market's growth and evolution.

Growing incidence of glioma

The growing incidence of glioma is a significant driver behind the expansion of the Glioma Treatment Market. Gliomas, a group of tumors originating in the brain and spinal cord, are known for their high morbidity and challenging treatment landscape. The increase in glioma cases is primarily attributed to various factors, including demographic shifts, environmental influences, and advancements in diagnostic techniques.

One key contributor to the rising incidence of glioma is the aging population. Gliomas are more commonly diagnosed in older individuals, and as many parts of the world experience demographic transitions towards older age groups, the number of glioma cases is expected to increase. The elderly population often faces a higher risk of developing these tumors, which has a direct impact on the demand for glioma treatments. The environmental and lifestyle factors play a role in the growing incidence of glioma. Exposure to ionizing radiation, including radiation therapy for other medical conditions, is a known risk factor for glioma development. The lifestyle factors such as smoking and certain dietary habits have been associated with an increased risk of glioma. As awareness of these risk factors grows, it prompts early intervention and diagnosis, leading to a higher number of glioma cases being detected. Advancements in diagnostic techniques have improved the early detection of glioma, a crucial factor driving the market. Advanced neuroimaging methods, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, offer greater sensitivity and specificity in identifying gliomas at their early, more treatable stages. This early detection enables prompt initiation of treatment, potentially leading to better patient outcomes and increasing the demand for glioma therapies.

The growing incidence of glioma is a substantial driver for the Glioma Treatment Market. The aging population, environmental influences, lifestyle factors, and enhanced diagnostic capabilities collectively contribute to the rising number of glioma cases. As the prevalence of these tumors increases, so does the demand for effective treatment options, spurring research and development efforts and shaping the market's continued growth.

Key Market Challenges

Resistance to therapies

Resistance to therapies stands as a significant challenge in the Glioma Treatment Market. Gliomas are notorious for their ability to develop resistance to various treatment modalities, including chemotherapy, targeted therapy, and immunotherapy. This resistance can result from the genetic heterogeneity within gliomas and the complex interplay of signaling pathways that allow tumor cells to evade the effects of treatment. As a result, initial responses to therapy may be promising, but over time, tumors often develop resistance, leading to treatment failure and disease progression. Overcoming therapy resistance remains a key focus of glioma research and treatment development to improve long-term patient outcomes.

Heterogeneity of gliomas

The heterogeneity of gliomas presents a substantial challenge in the Glioma Treatment Market. Gliomas are incredibly diverse in terms of their genetic and molecular characteristics, even among tumors that appear similar under the microscope. This diversity can lead to variations in treatment responses and poses a formidable obstacle for developing standardized therapies. Tailoring treatments to the unique genetic profiles of each glioma becomes complex, and patients may not all benefit from the same interventions. Researchers and clinicians are actively working to address this challenge by developing more personalized treatment strategies and refining therapeutic approaches to account for the heterogeneous nature of gliomas.

High treatment costs

High treatment costs pose a significant challenge in the Glioma Treatment Market. Glioma therapies, especially advanced treatments such as targeted therapies and immunotherapies, can be expensive. The financial burden on patients and healthcare systems is substantial, potentially limiting access to cutting-edge treatments. The long-term nature of glioma treatment, which often includes multiple surgeries, radiation therapy, and prolonged drug regimens, further contributes to the financial strain. The high cost of these treatments raises concerns about equitable access to care and the sustainability of healthcare systems. Addressing this challenge involves finding ways to make innovative glioma treatments more affordable and accessible to all patients.

Limited access to innovative treatments

Limited access to innovative treatments is a significant challenge in the Glioma Treatment Market. Despite the development of promising therapies, not all patients have equal access to these cutting-edge treatments. Geographic disparities, financial constraints, and variations in healthcare infrastructure can restrict patients' opportunities to benefit from the latest advancements in glioma treatment. Clinical trials, which are essential for testing new therapies, may not always be accessible to every patient. This challenge emphasizes the need for efforts to improve treatment accessibility and affordability, reduce healthcare disparities, and expand opportunities for patients to receive the most effective and innovative therapies for glioma.

Key Market Trends

Personalized Medicine

Personalized medicine is a prominent trend in the Glioma Treatment Market. It involves tailoring treatment strategies to the unique genetic and molecular characteristics of each patient's glioma. By conducting comprehensive genetic profiling and biomarker testing, healthcare providers can determine the most effective therapies for individual patients. This approach optimizes treatment outcomes, minimizes side effects, and enhances patient care. Personalized medicine has gained prominence as an innovative and patient-centric approach, fostering greater treatment precision and improving the prognosis for glioma patients. As research and technology continue to advance, the trend toward personalized medicine is expected to reshape the landscape of glioma treatment, offering more hope and customized care for patients.

Combination Therapies

Combination therapies are a significant trend in the Glioma Treatment Market. Gliomas' complex and heterogeneous nature often requires multifaceted approaches to combat resistance and improve treatment outcomes. Researchers are actively exploring combinations of treatment modalities, such as immunotherapies paired with targeted therapies or chemotherapy, to achieve synergistic effects. By simultaneously targeting different aspects of the disease, these combinations aim to enhance the overall therapeutic impact. Clinical trials are at the forefront of testing new combinations, offering hope for improved treatment responses and patient outcomes. Combination therapies reflect a growing understanding of the intricacies of gliomas and the need for more versatile and effective treatment strategies.

Immunotherapy advancements

Immunotherapy advancements are a prominent trend in the Glioma Treatment Market. Immunotherapies, particularly immune checkpoint inhibitors and vaccine-based approaches, are reshaping the treatment landscape for gliomas. Researchers are making significant progress in harnessing the patient's immune system to target and combat these brain tumors. Clinical trials are actively exploring immunotherapeutic agents, which have shown promise in extending patient survival and improving quality of life. With ongoing research and innovative developments in immunotherapy, the trend towards these novel approaches is poised to continue, offering renewed hope and more effective treatment options for glioma patients, ultimately altering the treatment paradigm in the years to come.

Enhanced neuroimaging

Enhanced neuroimaging is a significant trend in the Glioma Treatment Market. Advanced neuroimaging techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, offer higher sensitivity and precision in detecting and monitoring gliomas. These cutting-edge technologies enable clinicians to identify and characterize tumors with greater accuracy, facilitating early diagnosis and more informed treatment decisions. Enhanced neuroimaging also aids in the assessment of treatment response and the monitoring of disease progression. As these techniques continue to evolve, they are expected to play a pivotal role in improving patient outcomes by enabling earlier intervention and guiding personalized treatment strategies.

Patient-centered care models

Patient-centered care models are an emerging trend in the Glioma Treatment Market, emphasizing the holistic well-being of glioma patients. These models prioritize individualized care, improved communication between healthcare providers and patients, and the consideration of patient preferences and values in treatment decision-making. Patient advocacy and support have gained prominence, and initiatives aim to empower patients and their families with information and resources. This trend reflects a shift toward a more compassionate and comprehensive approach to glioma treatment, focusing not only on medical interventions but also on the overall quality of life and emotional support for patients, ultimately enhancing their treatment experience and outcomes.

Segmental Insights

Disease Insights

Based on the disease, Astrocytoma, a type of glioma, is a dominant segment in the Glioma Treatment Market. These tumors arise from astrocytes, a type of glial cell in the brain. Astrocytomas are among the most common gliomas and exhibit varying degrees of malignancy. Their prevalence and heterogeneity have led to extensive research and treatment development. Understanding and effectively treating astrocytomas is paramount in advancing glioma therapeutics. Targeted therapies and immunotherapies are being tailored to address specific genetic mutations commonly found in astrocytomas, underscoring their significance in shaping the treatment landscape. Clinical trials often focus on astrocytomas to evaluate new therapeutic approaches, further establishing their dominance in the market.

End User Insights

Based on end user, Hospitals and clinics play a dominant segment in the Glioma Treatment Market as the primary centers for diagnosis, treatment, and care of glioma patients. These healthcare facilities house specialized neuro-oncology departments equipped with advanced technology and expertise required for the complex management of gliomas. Neurosurgeons, oncologists, and multidisciplinary teams collaborate in hospitals and clinics to provide comprehensive care. The clinical trials, an essential aspect of glioma research and treatment development, are often conducted in hospital settings. Patients receive a continuum of care, from initial diagnosis through surgery, radiation therapy, chemotherapy, and follow-up, making hospitals and clinics central to the glioma treatment journey.

Regional Insights

Based on region, North America stands as a dominant region in the Glioma Treatment Market due to several key factors. This region exhibits a high incidence of gliomas, with the United States and Canada reporting substantial cases annually. The robust healthcare infrastructure, advanced medical technology, and a strong focus on research and development create fertile ground for innovative treatment options. The presence of leading pharmaceutical and biotechnology companies actively engaged in glioma research contributes to the market's growth. North America also hosts numerous clinical trials, offering patients access to cutting-edge therapies. These collective factors establish North America as a pivotal hub in advancing glioma treatment and research.

Key Market Players

F. Hoffmann-La Roche Ltd

Arbor Pharmaceuticals LLC

Merck & Co. KGaA

Sun Pharmaceutical Industries Ltd

Amgen Inc

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Amneal Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Biocon Ltd

Report Scope:

In this report, the Global Glioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glioma Treatment Market, By Disease:

    Astrocytoma Oligoastrocytoma Oligodendroglioma

Glioma Treatment Market, By Treatment Type:

    Surgery Chemotherapy Radiation Therapy Others

Glioma Treatment Market, By Grade:

    Low Grade High Grade

Glioma Treatment Market, By End user:

    Hospital & Clinics Ambulatory Surgical Centres Others

Glioma Treatment Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Glioma Treatment Market.

Available Customizations:

Global Glioma Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Glioma Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease (Astrocytoma, Oligoastrocytoma, Oligodendroglioma)
    • 4.2.2. By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Others)
    • 4.2.3. By Grade (Low Grade, High Grade)
    • 4.2.4. By End user (Hospital & Clinics, Ambulatory Surgical Centers, Others)
    • 4.2.5. By Region
    • 4.2.6. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Disease
    • 4.3.2. By Treatment Type
    • 4.3.3. By Grade
    • 4.3.4. By End user
    • 4.3.5. By Region

5. Asia Pacific Glioma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease
    • 5.2.2. By Treatment Type
    • 5.2.3. By Grade
    • 5.2.4. By End user
    • 5.2.5. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Glioma Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease
        • 5.3.1.2.2. By Treatment Type
        • 5.3.1.2.3. By Grade
        • 5.3.1.2.4. By End user
    • 5.3.2. India Glioma Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease
        • 5.3.2.2.2. By Treatment Type
        • 5.3.2.2.3. By Grade
        • 5.3.2.2.4. By End user
    • 5.3.3. Australia Glioma Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease
        • 5.3.3.2.2. By Treatment Type
        • 5.3.3.2.3. By Grade
        • 5.3.3.2.4. By End user
    • 5.3.4. Japan Glioma Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease
        • 5.3.4.2.2. By Treatment Type
        • 5.3.4.2.3. By Grade
        • 5.3.4.2.4. By End user
    • 5.3.5. South Korea Glioma Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease
        • 5.3.5.2.2. By Treatment Type
        • 5.3.5.2.3. By Grade
        • 5.3.5.2.4. By End user

6. Europe Glioma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Treatment Type
    • 6.2.3. By Grade
    • 6.2.4. By End user
    • 6.2.5. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Glioma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Grade
        • 6.3.1.2.4. By End user
    • 6.3.2. Germany Glioma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Grade
        • 6.3.2.2.4. By End user
    • 6.3.3. Spain Glioma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Grade
        • 6.3.3.2.4. By End user
    • 6.3.4. Italy Glioma Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease
        • 6.3.4.2.2. By Treatment Type
        • 6.3.4.2.3. By Grade
        • 6.3.4.2.4. By End user
    • 6.3.5. United Kingdom Glioma Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease
        • 6.3.5.2.2. By Treatment Type
        • 6.3.5.2.3. By Grade
        • 6.3.5.2.4. By End user

7. North America Glioma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Treatment Type
    • 7.2.3. By Grade
    • 7.2.4. By End user
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Glioma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Grade
        • 7.3.1.2.4. By End user
    • 7.3.2. Mexico Glioma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Grade
        • 7.3.2.2.4. By End user
    • 7.3.3. Canada Glioma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Grade
        • 7.3.3.2.4. By End user

8. South America Glioma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Treatment Type
    • 8.2.3. By Grade
    • 8.2.4. By End user
    • 8.2.5. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Glioma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Grade
        • 8.3.1.2.4. By End user
    • 8.3.2. Argentina Glioma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Grade
        • 8.3.2.2.4. By End user
    • 8.3.3. Colombia Glioma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Grade
        • 8.3.3.2.4. By End user

9. Middle East and Africa Glioma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Treatment Type
    • 9.2.3. By Grade
    • 9.2.4. By End user
    • 9.2.5. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Glioma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Grade
        • 9.3.1.2.4. By End user
    • 9.3.2. Saudi Arabia Glioma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Grade
        • 9.3.2.2.4. By End user
    • 9.3.3. UAE Glioma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Grade
        • 9.3.3.2.4. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Glioma Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. F. Hoffmann-La Roche Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Arbor Pharmaceuticals LLC
  • 14.3. Merck & Co. KGaA
  • 14.4. Sun Pharmaceutical Industries Ltd
  • 14.5. Amgen Inc
  • 14.6. Teva Pharmaceutical Industries Ltd
  • 14.7. Pfizer Inc
  • 14.8. Amneal Pharmaceuticals Inc
  • 14.9. Karyopharm Therapeutics Inc
  • 14.10.Biocon Ltd

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제